Condition
Tumor
Estimated Enrollment: 35
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: PXD101-CLN-4
Study First Received: December 18, 2006
Last Updated: July 7, 2015
Estimated Primary Completion Date: March 2008
Primary Outcome Measures:
to determine the maximum tolerated dose of PXD101 administered in combination with 5-FU|to determine whether PXD101 alone can down-regulate thymidylate synthase in patient tumors
Sponsors and Collaborators:
Onxeo
Website Link: https://ClinicalTrials.gov/show/NCT00413322
